



## OPEN ACCESS

## APPROVED BY

Frontiers in Pharmacology  
Editorial Office, Frontiers Media SA,  
Switzerland

## \*CORRESPONDENCE

Frontiers Production Office,  
✉ production.office@frontiersin.org

RECEIVED 27 April 2023

ACCEPTED 27 April 2023

PUBLISHED 05 May 2023

## CITATION

Frontiers Production Office (2023),  
Erratum: Comparison between  
decitabine and azacitidine for patients  
with acute myeloid leukemia and higher-  
risk myelodysplastic syndrome: a  
systematic review and network meta-  
analysis.

*Front. Pharmacol.* 14:1213053.

doi: 10.3389/fphar.2023.1213053

## COPYRIGHT

© 2023 Frontiers Production Office. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction in  
other forums is permitted, provided the  
original author(s) and the copyright  
owner(s) are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

decitabine, azacitidine, acute myeloid leukemia, higher-risk myelodysplastic syndrome, network meta-analysis

## An Erratum on

[Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis](#)


by Ma J and Ge Z (2021). *Front. Pharmacol.* 12:701690. doi: 10.3389/fphar.2021.701690

Due to a production error, there was a mistake in the legends for [Figures 6–8](#) as published. The legend of [Figure 6](#) matches the graph of [Figure 7](#), the legend of [Figure 7](#) matches the graph of [Figure 8](#), and the legend of [Figure 8](#) matches the graph of [Figure 6](#). The correct legends appear below. The publisher apologizes for this mistake.


The original version of this article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



**FIGURE 6**  
Forest plot of efficacy represents the direct and indirect comparison.



**FIGURE 7**  
Forest plot of grade 3/4 adverse events of azacitidine vs. conventional care regimens (direct evidence-RR).




FIGURE 8 Forest plot of grade 3/4 adverse events of decitabine vs. conventional care regimens (direct evidence-RR).